Apraglutide, a novel glucagon‐like peptide‐2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo‐controlled, randomized phase 2 trial

BACKGROUND: Treatment with glucagon‐like peptide‐2 (GLP‐2) analogs improve intestinal adaptation in patients with short bowel syndrome–associated intestinal failure (SBS‐IF) and may reduce parenteral support requirements. Apraglutide is a novel, long‐acting GLP‐2 analog designed for once‐weekly dosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliasson, Johanna, Hvistendahl, Mark K., Freund, Nanna, Bolognani, Federico, Meyer, Christian, Jeppesen, Palle B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292678/
https://www.ncbi.nlm.nih.gov/pubmed/34287970
http://dx.doi.org/10.1002/jpen.2223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292678/
https://www.ncbi.nlm.nih.gov/pubmed/34287970
http://dx.doi.org/10.1002/jpen.2223

Ejemplares similares